Fluor Corporation (NYSE: FLR) announced that it has received a letter of intent from a leading global pharmaceutical company to provide engineering, procurement, and construction management (EPCM) services for a major manufacturing facility in Lebanon, Indiana. The company will recognize the multi-billion-dollar reimbursable contract as a new award in the first quarter of 2025.
This latest investment follows Fluor’s initial multi-billion-dollar project awarded in 2023 and marks another significant milestone in the expansion of advanced pharmaceutical manufacturing in the U.S.
The new facility will produce innovative peptide-based drugs for Type 2 diabetes and weight management, representing the largest-ever investment in an active pharmaceutical ingredient (API) facility in U.S. history.
“This monumental project is one of the largest life sciences initiatives ever undertaken in a single phase and reinforces Fluor’s leadership in EPCM for the sector,” said Richard Meserole, President of Fluor’s Advanced Technologies & Life Sciences business. “The therapies manufactured here have the potential to improve the lives of millions worldwide, and Fluor is honored to be a part of this transformative effort.”
About Fluor Corporation
Fluor Corporation (NYSE: FLR) is committed to building a better world by leveraging world-class expertise to address its clients’ most complex challenges. With nearly 27,000 employees, Fluor delivers safe, well-executed, and capital-efficient projects across industries worldwide. The company reported $16.3 billion in revenue in 2024 and is ranked 265 on the Fortune 500 list. Headquartered in Irving, Texas, Fluor has been providing engineering, procurement, and construction services for more than a century.